1887
Volume 2014, Issue 1
  • ISSN: 2305-7823
  • E-ISSN:

There is no abstract available for this article.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.1
2014-06-01
2019-12-07
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/1/gcsp.2014.1.html?itemId=/content/journals/10.5339/gcsp.2014.1&mimeType=html&fmt=ahah

References

  1. Kaba RA, Ahmed O, Cannie D. ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. Glob Cardiol Sci Pract. 2013; 2013:4:354356.
    [Google Scholar]
  2. Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother. 2012 Dec; 46:12:16271636.
    [Google Scholar]
  3. Sarma A. Novel Oral Anticoagulants and Lack of Reversibility. Cardiosource.org. Accessed 1/11/2014.
  4. Laulicht B, Bakhru S, Lee C, Baker C, Jiang X, Mathiowitz E, Costin J, Steiner S. Small Molecule Antidote for Anticoagulants. Circulation. 2012 Nov; 126:21S:A11395.
    [Google Scholar]
  5. Mark C, Vandana M, Michael K, Genmin L, Conley PB, Stanley H, Castillo J, Hutchaleelaha A, Karbarz M, Lin JP, Barron L, Russell S, Levy GG, Connolly S, Curnutte JT. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. Blood. 2013 Oct; 122:21:3636.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.1
Loading
  • Article Type: Letter
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error